Japanese doctors fears on generics

24 September 2006

Some 81.9% of Japanese physicians are concerned about providing information on generic drugs which they get from their manufacturers, according to a survey conducted by the Japan Medical Association.

The JMA conducted the survey to confirm how its members see the generic drugs under the current circumstances where the use of such products is being promoted in Japan, targeting the members via the JMA's home page from May 27 through to the end of July. 557 physicians responded to the questionnaire survey on the Internet.

In addition to the provision of information, 68.8% and 68.5% of physicians are concerned about efficacy and stable supply in generic drugs, respectively. 53.8% and 44.8%, respectively, are worried about the quality and side effects of copy-cat products. Asked about generic drugs in general, 67.4% are cautious or skeptical, while only 16.9% have positive and favorable opinions. The rest take a middle position.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight